期刊
EXPERT REVIEW OF CLINICAL PHARMACOLOGY
卷 9, 期 3, 页码 355-365出版社
TAYLOR & FRANCIS LTD
DOI: 10.1586/17512433.2016.1133285
关键词
refractory; salvage line; metastatic colorectal cancer; TAS-102; phase III; intolerant; chemotherapy
资金
- Taiho Pharmaceutical Co., Ltd.
TAS-102 is a new oral anti-tumor drug, composed of a thymidine-based nucleoside analog (trifluridine: FTD) and a thymidine phosphorylase inhibitor (tipiracil hydrochloride: TPI). TAS-102 has been shown to significantly improve overall survival and progression-free survival in patients with refractory metastatic colorectal cancer (mCRC) in placebo-controlled randomized phase II and III trials. The current review summarizes mechanisms of action, pharmacokinetics/dynamics and preclinical and clinical data of TAS-102 in colorectal cancer. TAS-102 is a new salvage-line treatment option for patients with mCRC. TAS-102 is well tolerated and has great potential in future clinical drug combination therapies.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据